Clinical Trial: NCT04846920
A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)
Status:
COMPLETEDPhase:
Phase 1| Lead Sponsor: | Merck Sharp & Dohme LLC |
| Information Provided By: | Merck Sharp & Dohme LLC |
| Last Update Posted: | 2026-05-22 |
Study Overview
Brief Summary
The goal of this study is to evaluate the safety, tolerability and pharmacokinetics of escalating doses of belzutifan as second line positive (2L+) treatment in participants with advanced clear cell renal cell carcinoma (ccRCC).
Official Title
A Phase 1, Dose-escalation Study to Evaluate Safety and Tolerability of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Conditions
Carcinoma, Renal Cell
Intervention / Treatment
- Drug: Belzutifan
Other Study ID Numbers
- 6482-018
- MK-6482-018
Start Date (Actual)
2021-06-14
Primary Completion Date (Actual)
2026-04-11
Study Completion Date (Actual)
2026-04-11
Enrollment (Actual)
29
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | Merck Sharp & Dohme LLC |
| Information Provided By: | Merck Sharp & Dohme LLC |
| Last Update Posted: | 2026-05-22 |
Study Overview
Brief Summary
The goal of this study is to evaluate the safety, tolerability and pharmacokinetics of escalating doses of belzutifan as second line positive (2L+) treatment in participants with advanced clear cell renal cell carcinoma (ccRCC).
Official Title
A Phase 1, Dose-escalation Study to Evaluate Safety and Tolerability of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Conditions
Carcinoma, Renal Cell
Intervention / Treatment
- Drug: Belzutifan
Other Study ID Numbers
- 6482-018
- MK-6482-018
Start Date (Actual)
2021-06-14
Primary Completion Date (Actual)
2026-04-11
Study Completion Date (Actual)
2026-04-11
Enrollment (Actual)
29
Study Type
Interventional
Phase
Phase 1